Cognition Therapeutics, Inc.

NASDAQ:CGTX

Biotechnology

Healthcare
$0.60 -0.70%

-$0.01 today

Market cap
$57.06M
Beta
1.75
P/E (TTM)
-6.4
EPS (TTM)
-$0.22
52W Low $0.25High $3.83

Volume 0.34M

Average 1.23M

CGTX Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Cognition Therapeutics, Inc.NASDAQ: CGTX

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $5.54M (cash outflow) fell 43.9% year over year, behind the -34.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 61.2% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.

Context

  • Free cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -43.9% toward the trailing-twelve-month pace of -34.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.54M+61.2% QoQ
Last fiscal yearDec 2025
-$24.59M-13.7% YoY
LTMMar 2026
-$20.25M-34.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.9%——
1 year-13.7%——
3-year CAGR+9.5%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(24.59M) USD
Year-over-year change
+13.7%

Free Cash Flow vs competitors

How CGTX compares with its peers on the latest reported figures

  • CGTX's LTM Mar 2026 free cash flow of $20.25M is the 6th largest of the 8 companies compared; the peer median is $38.99M.
  • Its year-over-year change of -34.9% is the 6th highest of 8, against a peer median of +35.1%.
  • Over three fiscal years its annual growth of +9.5% compares with a peer median of -11.4%.
CGTX Competitors Peer median
Free Cash Flow for CGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$87.53M -40.2%-11.4%70.7%
SEERSeer, Inc.LTM Mar 2026$49.88M -1.3%-13.3%331.7%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$42.37M -51.2%—3694.1%
IRDOpus Genetics, Inc.LTM Mar 2026$38.99M +35.1%—325.3%
SRZNSurrozen, Inc.LTM Mar 2026$33.68M +85.0%-12.2%449.4%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$20.25M -34.9%+9.5%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$12.78M +74.6%+16.9%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$7.24M +121.7%+17.8%13.2%
Peer median (excluding CGTX) $38.99M+35.1%-11.4%328.5%

Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(11.72M)(21.4M)(25.79M)(33.97M)(23.49M)
Depreciation & Amortization93K235K252K266K228K
Deferred Income Tax00000
Stock-Based Compensation5.18M3.57M4.35M3.75M2.09M
Change in Working Capital2.84M(943K)4.85M1.29M(3.46M)
Accounts Receivables(1.11M)(1.41M)2.39M(1.41M)(7.24M)
Inventory00000
Accounts Payables2.17M(1.09M)003.51M
Other Working Capital1.79M1.56M2.46M2.69M270K
Other Non-Cash Items(33K)0318K195K41K
Operating Cash Flow(3.63M)(18.53M)(16.02M)(28.47M)(24.59M)
Capital Expenditures(27K)(171K)(147K)(4K)0
Acquisitions (Net)00009K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(27K)(171K)(147K)(4K)9K
Debt Repayment(268K)(1.4M)(811K)(739K)(353K)
Common Stock Issued44.22M5.32M5.33M24.35M37.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.25M1.62M0(46K)(164K)
Financing Cash Flow53.2M5.55M4.52M23.57M36.57M
Effect of Forex Changes(11K)(1K)4K00
Net Change in Cash49.53M(13.16M)(11.64M)(4.91M)11.99M
Free Cash Flow(3.66M)(18.7M)(16.17M)(28.48M)(24.59M)

Cognition Therapeutics, Inc.

NASDAQ:CGTX

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.